Tirzepatide in Australia — research guide, purity and pricing

Tirzepatide is a synthetic peptide that binds both the GIP and GLP-1 receptors. Unlike single-agonist peptides such as Semaglutide, its dual activity is the focus of most comparative research.

In Australia, prescription medicines containing tirzepatide are separately regulated. Material supplied here is a laboratory reference standard, not a medicine, and is not supplied for human use.

Published work spans receptor pharmacology, comparative agonist studies against single-receptor peptides, and clinical trial programmes run by the compound's developer.

We do not reproduce trial results. Use the PubMed link below to read the primary literature.

Lyophilised (freeze-dried) peptides are shipped cold-chain packed and are typically stored at -20°C for long-term storage, or 2-8°C for short periods before reconstitution.

Once reconstituted with bacteriostatic water, vials are generally refrigerated at 2-8°C and protected from light and repeated freeze-thaw cycles.

Every Aussie Peptides vial carries a lot number that maps to a batch Certificate of Analysis, so purity and identity can be recorded alongside your experimental data.

Materials on this site are supplied strictly for in-vitro laboratory research. They are not therapeutic goods, are not approved by the TGA for human use, and are not supplied for human or veterinary consumption.

Purchasers must be 18 or over and are responsible for handling, storing and disposing of research materials in line with their institution's requirements and applicable Australian law.

Nothing on this page is medical advice, a dosing protocol, or a claim of therapeutic benefit. It summarises what the published research literature investigates.